Agios Pharma (AGIO) Misses Q3 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to Agios Pharma (AGIO) Misses Q3 EPS by 3c

Agios Reports Third Quarter 2018 Financial Results

November 1, 2018 7:00 AM EDT

Supplemental New Drug Application Submission for Single Agent TIBSOVO® (ivosidenib) in Newly Diagnosed IDH1m AML Patients Not Eligible for Standard Treatment Planned by the End of January 2019

Enrollment for Phase 3 AGILE Trial of Ivosidenib Combination with Azacitidine in Newly Diagnosed AML Patients Not Eligible for Intensive Chemotherapy Expected to Complete in 2020 with Revised Primary Endpoint

Mitapivat Pivotal Trials ACTIVATE and ACTIVATE-T in Adults with PK Deficiency Expected to Complete Enrollment in 2019

TIBSOVO® Launch in R/R IDH1m AML On-track; Reported Revenue of $4.5M in First Partial... More